Genetic ablation of the mitoribosome in the malaria parasite 
*Plasmodium falciparum* sensitizes it to antimalarials that target mitochondrial functions

Liqin Ling‡1, © Maruthi Mulaka‡1, © Justin Munro‡, Swati Dass‡, © Michael W. Mather‖, Michael K. Riscoe†, ‡ Manuel Llinás*****, Jing Zhou‡2, and Hangjun Ke‡3

From the ‡Department of Chemistry and Huck Center for Malaria Research, Pennsylvania State University, University Park, Pennsylvania 16802, †Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania 16802, §2 Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China, the ††Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania 16802, and the ‡‡Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.

The mitochondrion of malaria parasites contains several clinically validated drug targets. Within *Plasmodium* spp., the causative agents of malaria, the mitochondrial DNA (mtDNA) is only 6 kb long, being the smallest mitochondrial genome among all eukaryotes. The mtDNA encodes only three proteins of the mitochondrial electron transport chain and ~27 small, fragmented rRNA genes having lengths of 22–195 nucleotides. The rRNA fragments are thought to form a mitochondrial ribosome (mitoribosome), together with ribosomal proteins imported from the cytosol. The mitoribosome of *Plasmodium falciparum* is essential for maintenance of the mitochondrial membrane potential and parasite viability. However, the role of the mitoribosome in sustaining the metabolic status of the parasite mitochondrion remains unclear. The small ribosomal subunit in *P. falciparum* has 14 annotated mitoribosomal proteins, and employing a CRISPR/Cas9-based conditional knockdown tool, here we verified the location and tested the essentiality of three candidates (PfmtRPS12, PfmtRPS17, and PfmtRPS18). Using immuno-EM, we provide evidence that the *P. falciparum* mitoribosome is closely associated with the mitochondrial inner membrane. Upon knockdown of the mitoribosome, parasites became hypersensitive to inhibitors targeting mitochondrial Complex III (bc1), dihydroorotate dehydrogenase (DHOD), and the F1F0-ATP synthase complex. Furthermore, the mitoribosome knockdown blocked the pyrimidine biosynthesis pathway and reduced the cellular pool of pyrimidine nucleotides. These results suggest that disruption of the *P. falciparum* mitoribosome compromises the metabolic capacity of the mitochondrion, rendering the parasite hypersensitive to a panel of inhibitors that target mitochondrial functions.

Despite substantial success in reducing malaria morbidity and mortality over the last 15 years, malaria control has now encountered a serious bottleneck (1–3). Since 2015, statistics of global malaria illness (over 200 million cases per year) and death (~half a million per year) have remained almost static (1–3). In fact, malaria incidence had an increase of ~5 million cases in 2016 alone (2), indicating a risk of resurgence of this devastating disease. To better combat malaria and potentially reach the goal of eradication, a deep understanding of the malaria parasite, a eukaryotic protozoan in the genus of *Plasmodium*, is urgently needed. Among the five *Plasmodium* species that infect humans, *Plasmodium falciparum* is responsible for more than 80% of the clinical cases and 90% of deaths. *P. falciparum* contains three distinct genomes, residing in the nucleus, the apicoplast (a relict nonphotosynthetic plastid), and the mitochondrion (4). The spatial distribution of genetic materials in the three subcellular compartments necessitates three distinct translation systems to translate local mRNAs to proteins. Although the cytoplasmic ribosome resembles an 80S eukaryotic ribosome with some parasite-specific features (5, 6), ribosomes in the organelles are of bacterial origin (7, 8), which hold promise as novel antimalarial drug targets. The apicoplast ribosome has been long recognized as the target of several antibiotics (*e.g.* erythromycin and clindamycin) that exhibit a delayed death effect (9–11). However, the mitochondrial ribosome (mitoribosome) of malaria parasites has remained enigmatic.

In the mitochondria of eukaryotic cells, mitoribosomes translate genes encoded on the mitochondrial DNA (mtDNA),

---

1. Both authors contributed equally to this article.
2. To whom correspondence may be addressed. E-mail: zhoujinghuaxi@163.com.
3. To whom correspondence may be addressed: 2900 Queen Lane, Philadelphia, PA 19129. Tel.: 215-991-8448; Fax: 215-848-2271; E-mail: hk84@drexel.edu.
4. The abbreviations used are: mtDNA, mitochondrial DNA; PfmtRPS12, *P. falciparum* mitochondrial ribosomal protein S12; PfmtRPS17, *P. falciparum* mitochondrial ribosomal protein S17; PfmtRPS18, *P. falciparum* mitochondrial--
Small subunit proteins in the P. falciparum mitoribosome

the majority of which are protein subunits of the mitochondrial electron transport chain (mtETC). Human mtDNA is a circular molecule of 16.6 kb, encoding 13 proteins, 22 tRNA genes, and 2 mitochondrial ribosomal RNA (rRNA) genes (12S and 16S) (12). However, in malaria parasites and other members of the phylum Apicomplexa, reductive evolution has likely driven the size of mtDNA to a minimum (13). Being an extreme case, e.g. the linear 6-kb mtDNA of malaria parasites is the smallest organellar genome among the entire Eukarya (14–16). It is highly compact, encoding only three proteins (cytochrome b, cytochrome c oxidase subunits I and III (cox1, cox3)), fragmented rRNA genes, but no tRNAs or other open reading frames (17). The three proteins comprise the highly hydrophobic cores of two proton pumps of the Plasmodium mtETC, Complex III (bc1 complex) and Complex IV (cytochrome c oxidase), with the estimated number of transmembrane helices present in the cyt b, cox1, and cox3 subunits being 9, 13, and 7, respectively (TMHMM Server, v.2.0). The importance of mitochondrial protein translation in malaria parasites is underscored by the fact that the bc1 complex is a major antimarial drug target. The clinical drug atovaquone, a hydroxynaphthoquinone, targets the Qo site of bc1 complex, substantially collapses the mitochondrial membrane potential (ΔΨm), and halts parasite growth (18–20). A long list of structurally distinct bc1 inhibitors are currently in the drug development pipeline (21), including the preclinical candidate, ELQ-300 (inhibitor of Qi site). ELQ-300 is highly potent and selective, long lasting, and effective against multiple lifecycle stages (22–24). Despite the significance of the mtETC, how the critical subunits are translated in the parasite mitochondrion is still poorly understood.

Arguably, the Plasmodium mitoribosome represents an unusually atypical ribosome due to its RNA composition consisting of many small and fragmented pieces (17). The 6-kb mtDNA encodes 27 rRNA “minigenes” annotated to be integrated into the small subunit (SSU, 12 rRNAs) and the large subunit (LSU, 15 rRNAs) of the mitoribosome (17). These rRNA fragments are sized between 22 and 195 nucleotides. Importantly, the short fragmented rRNA genes can be mapped to the core conserved structures of bacterial SSU and LSU rRNAs (16S and 23S) (17), suggesting their potential roles in protein synthesis. Fragmented mitoribosomal rRNAs have been observed in other free living single-celled organisms such as the ciliate Tetrahymena thermophila (6 fragmented rRNAs) (25) or the green alga Chlamydomonas reinhardtii (12 fragmented rRNAs) (26). However, the degree of rRNA fragmentation observed in the mitoribosome of malaria parasites greatly surpasses these examples. Recent ground-breaking advancements in cryo-EM technology have resolved the structures of mitoribosomes from yeast (27, 28), mammals (29–34), and Trypanosoma brucei (a protist) (35). These studies have greatly increased our understanding of mitoribosomes and interactions of rRNA and ribosomal proteins (rProteins). However, all of these organisms contain long and continuous rRNAs in the mitoribosome, including T. brucei, which has relatively small rRNA genes (95/620 nucleotides, 125/1176 nucleotides) (35).

Although knowledge of mitoribosomes composed of numerous fragmented rRNAs has remained limited, we recently verified the essentiality of the P. falciparum mitoribosome for the first time (36), using a CRISPR/Cas9-mediated conditional knockdown technique, the TetR-DOZI-aptamer system (37). We showed that knockdown of the conserved mitoribosomal LSU protein, PfmRPL13 (PF3D7_0214200), caused a loss of ΔΨm, followed by parasite death (36). The essential nature of the mitoribosome in Toxoplasma gondii, another apicomplexan parasite, has also been reported (38). However, there is no literature on any of 14 annotated SSU proteins in Plasmodium (PlasmoDB, RRID: SCR_013331). Here, we report data on three annotated SSU proteins, PfmRPS12 (PF3D7_0412100), PfmRPS17 (PF3D7_1365100), and PfmRPS18 (PF3D7_1211500) in P. falciparum. In particular, genetic knockdown of PfmRPS12 caused the parasites to become hypersensitive to a panel of antimarial drugs that target mitochondrial functions.

Results

A predicted map of the Plasmodium mitoribosome SSU

In Plasmodium spp., there are a total of 41 annotated mitoribosomal proteins (8), most of which are universally conserved proteins present in all ribosomes (PlasmoDB, RRID: SCR_013331). The SSU of the Plasmodium mitoribosome is composed of 14 annotated proteins, at least 12 fragmented rRNAs, and likely a number of additional ribosomal proteins that are not identifiable via currently available bioinformatics approaches. Based on the assembly map of the well-studied bacterial 30S ribosome (39) and the 6-kb sequence of Plasmodium mtDNA (17), we predicted relative positions of 12 mitoribosomal rRNA fragments in 5’ to 3’ directions according to their homology to different domains of the 16S rRNA molecule (Fig. 1). The likely interactions of rRNA fragments and 14 annotated mitoribosomal proteins are also illustrated (Fig. 1). Bacterial SSU proteins are classified into three categories according to the assembly hierarchy: primary (1*), secondary (2*), and tertiary (3*) (39). As shown in Fig. 1, Plasmodium contains at least 3 of 6 primary SSU proteins. Primary SSU proteins directly bind rRNA in the bacterial ribosome (39). Plasmodium also contains at least 4 of 6 secondary SSU proteins and 4 of 8 tertiary SSU proteins. In addition, 3 extra annotated SSU proteins in Plasmodium (S22, S29, and S35) have no bacterial homologs; hence, the positions of these three were not predicted. Recent work on T. gondii, another apicomplexan parasite, showed that TgmS35 (TGME49_203620) is localized in the parasite mitochondrion and is essential for parasite growth (38). From the list of 14 Plasmodium SSU proteins, in this study, we chose to work with
three putative proteins: one primary (PfmtRPS17, PF3D7_1365100), one secondary (PfmtRPS18, PF3D7_1211500), and one tertiary (PfmtRPS12, PF3D7_0412100).

PfmtRPS12, PfmtRPS17, and PfmtRPS18 are mitochondrial proteins

To determine whether PfmtRPS12, PfmtRPS17, and PfmtRPS18 actually localize to the mitochondrion in *P. falciparum*, and if they are essential for parasite growth in asexual blood stages, we used a recently developed translational knockdown approach, the TetR-DOZI-aptamer system (37). Three transgenic parasite lines, D10-PfmtRPS12–3HA, D10-PfmtRPS17–3HA, and D10-PfmtRPS18–3HA were generated from the D10 WT to individually tag and control expression of the three subunits (“Experimental procedures”). As shown in Fig. S1A, the SSU genes were individually tagged with a triple HA tag. Meanwhile, the elements of the TetR-DOZI-aptamer system were also integrated at the genomic loci via the double cross-over recombination approach facilitated by CRISPR/Cas9. As depicted in Fig. 1B, translation of the tagged mRNA was conditionally regulated by addition (ON) or removal (OFF) of the small molecule, anhydrotetracycline (aTc) (37). The genotype of each SSU transgenic line was confirmed by diagnostic PCR analysis (Fig. S1C). The expression of the tagged SSU proteins was confirmed by Western blotting, as shown in Fig. 2A. The localization of each SSU protein was then examined by immunofluorescence assay (IFA); all three localized to the mitochondrion (Fig. 2B). The mitochondrial morphologies of D10 WT parasites that were pre-loaded with MitoTracker and fixed with 4% paraformaldehyde, 0.0075% glutaraldehyde are shown in Fig. S3.

**PfmtRPS18 appears to be located on the mitochondrial inner membrane**

Our IFA data suggest that these three proteins are likely mitoribosomal proteins in the *Plasmodium* mitochondrion (Fig. 2). Because mitoribosomes translate highly hydrophobic proteins of the mtETC, the exit tunnel is generally positioned toward the mitochondrial inner membrane (MIM) and directly contacts the MIM (40). This close interaction of mitoribosomes and MIM facilitates co-translational insertion of the multi-transmembrane protein products into the mtETC, which has been observed in mitochondria of several organisms (40). We used immunoelectron microscopy (immuno-EM) to verify if our tagged SSU proteins had a close proximity to the MIM. Because immuno-EM is technically more challenging than IFA, we chose to proceed with one SSU protein that has a relatively high expression level. A previous proteomic study that quantified expression profiles of over 2,000 proteins in the asexual blood stage of *P. falciparum* detected the expression level of PfmtRPS18 at the 75th percentile relative to the levels found among the pool that contained trophozoite and schizont stage samples (41). The expression of PfmtRPS12 or PfmtRPS17, on the other hand, did not appear to be abundant enough for proteomic studies (41). Hence, we enriched D10-PfmtRPS18–3HA parasites using a magnetic column and performed immuno-EM studies (“Experimental procedures”). Although gold particles sometimes were present at other sites, the majority were found in the mitochondria at or very near the MIM (Fig. 3, A and B). In particular, quantification of gold particles from two biological experiments revealed the particles were localized to the mitochondria (at or near MIM) at 66.8%, the cytoplasm at 11.1%, the endoplasmic reticulum at 10%, the nucleus at 1.1%, and the nuclear membrane at 0.8%.
Small subunit proteins in the *P. falciparum* mitoribosome

at 8.7%, and others at 3.4%. Hence, our data indicate that PfmtRPS18 was likely associated with the MIM. As a negative control, omission of the primary antibody had a clean background (Fig. 3C). Together, these data suggest the *Plasmodium* mitoribosome is likely bound to the mitochondrial inner membrane, as in other organisms.

**Loss of distinct SSU proteins leads to different growth phenotypes**

Because these three SSU proteins likely occupy distinct sites in the mitoribosome (Fig. 1), we wanted to know whether a genetic ablation of each individual protein would cause similar or different growth phenotypes. Using the TetR-DOZI-ap-
Small subunit proteins in the P. falciparum mitoribosome

Figure 4. Effect on parasite survival upon individual knockdown of PfmtRPS12, PfmtRPS17, and PfmtRPS18. Representative growth curves of D10-PfmtRPS12–3HA (A), D10-PfmtRPS17–3HA (B), or D10-PfmtRPS18–3HA (C) grown in aTc− (blue) and aTc+ (red) conditions. Growth index is the cumulative parasitemia, which is the multiplication of parasitemia and split factors (1:5 split every IDC) over the time course. Data shown are the mean ± S.D. of three biological replicates (n = 3).

tamer system (37), expression of three mitoribosomal proteins was regulated by aTc (Fig. 1B). Previously we found that 250 nM aTc itself did not interfere with growth of D10 WT parasites (36). The three SSU transgenic lines were maintained in aTc medium (250 nM) prior to knockdown assays. To individually assess the essentiality of three SSU subunits of the P. falciparum mitoribosome, we set up knockdown assays in the transgenic lines and monitored parasite growth over five erythrocytic cycles (IDCs) (“Experimental procedures”). In particular, to minimize aTc carryover, the parasitized RBCs were isolated by a Percoll gradient and exposed to medium with or without 250 nM aTc (“Experimental procedures”). The knockdown efficiency was confirmed by Western blotting, as shown in Fig. S2; expression of SSU proteins was substantially decreased in knockdown parasites after aTc removal.

We found that knockdown of different SSU proteins resulted in distinct growth defects. As shown in Fig. 4B, knocking down PfmtRPS17 caused a severe growth arrest. Although the parasite appeared morphologically healthy under a light microscope after aTc had been removed for 1 IDC, detrimental changes were observed after 2 IDCs without aTc (Fig. S4B). After aTc removal for 3 IDCs or longer, D10-PfmtRPS17–3HA parasites were severely deteriorated. The essentiality of the PfmtRPS17 subunit is consistent with the fact that the bacterial S17 is a critical protein for assembly of the 30S ribosome. It directly binds to the 5′ end of 16S rRNA to stabilize the first step of SSU assembly (42). Knocking down PfmtRPS12, on the other hand, resulted in a mild growth arrest. As shown in Fig. 4A and Fig. S4, in the first 2 IDCs without aTc, PfmtRPS12 parasites did not exhibit a loss in parasitemia or any detectable abnormality in morphology; however, the parasites started to show a decrease in growth rate in the 3rd IDC (~20% loss) and more noticeably in the 4th IDC (~50% loss). After withdrawal of aTc for 4 or 5 IDCs, some PfmtRPS12 parasites displayed noticeable abnormalities in morphology (Fig. S4A). Despite these defects in growth rate and parasite morphology, PfmtRPS12 parasites were able to continuously grow after aTc removal for longer than 5 IDCs (data not shown). Previous studies in the 30S ribosome have shown that the bacterial S12 protein does not directly bind to 16S rRNA, but rather is involved in tRNA selection in the decoding center of the SSU (43). The mild phenotype seen upon knockdown of PfmtRPS12 suggests that this Plasmodium homolog has a significant but perhaps not critical function in the mitoribosomal complex.

Figure 5. Mitochondria show distinct growth defects. For example, mitochondria from D10-PfmtRPS18–3HA parasites were isolated after aTc removal for different numbers of IDCs and assessed for growth following aTc removal. The principle of mitochondrial protein translation. Hence, we isolated mitochondria from our SSU transgenic parasites grown in large culture volumes with and without aTc and assayed the bc1 activity in each mitochondrial preparation (“Experimental procedures”). Because knockdown of individual SSU proteins led to distinct growth defects (Fig. 4), mitochondria were harvested after a different number of IDCs of growth following aTc removal. The principle of bc1 enzymatic activity in extracts of parasites grown in vitro (36), which in turn reflects the efficiency of mitochondrial protein translation.

Loss of distinct SSU proteins results in a decrease in bc1 enzymatic activity

In Plasmodium, the mitoribosome solely translates three proteins that are incorporated into the bc1 complex (cyt b) and Complex IV (cox1 and cox3). Due to lack of antibodies against these proteins, a direct measurement of these protein products in our knockdown parasites is not feasible at present. We have previously established a protocol to measure the bc1 enzymatic activity in extracts of parasites grown in vitro (36), which in turn reflects the efficiency of mitochondrial protein translation. Hence, we isolated mitochondria from our SSU transgenic parasites grown in large culture volumes with and without aTc and harvested them at the 4th IDC after withdrawal of aTc when they showed moderate growth defects. Because PfmtRPS18 knockdown produced no detectable growth defects, mitochondria from D10-PfmtRPS18–3HA parasites were isolated in cultures...
maintained without aTc for 5 IDCs. As controls, mitochondria from D10-PfmtRPS12–3HA, D10-PfmtRPS17–3HA, and D10-PfmtRPS18–3HA parasites were isolated in cultures grown continuously in the presence of aTc.

As shown in Fig. 5B, in all three SSU knockdown parasite lines, the enzymatic activity of bc1 was significantly compromised. Compared with that of the controls, the bc1 enzymatic ability was reduced by 52% in D10-PfmtRPS12–3HA knockdown parasites, 53% in D10-PfmtRPS17–3HA knockdown parasites, and 30% in D10-PfmtRPS18–3HA knockdown parasites. As a control, 1 μM atovaquone completely diminished the bc1 enzymatic activity, validating the assay. Although all three knockdown lines lost significant bc1 enzymatic activity, knockdown of PfmtRPS18 had a milder effect on bc1 than that of PfmtRPS12 or PfmtRPS17. As a control, 1 μM atovaquone completely diminished the bc1 enzymatic activity, validating the assay. Although all three knockdown lines lost significant bc1 enzymatic activity, knockdown of PfmtRPS18 had a milder effect on bc1 than that of PfmtRPS12 or PfmtRPS17. This is consistent with the nonessential role of PfmtRPS18 in parasite survival as shown in Fig. 4C. However, it is interesting to note that PfmtRPS18 parasites can tolerate a 30% loss in bc1 activity without suffering any noticeable morphological changes or growth defects. In both PfmtRPS12 and PfmtRPS17 lines, the effect of knockdown on the bc1 enzymatic activity was similar; however, a longer period of aTc removal was needed in PfmtRPS12 (4 IDCs) as compared with PfmtRPS17 (2 IDCs) to reduce bc1 activity by >50%. Overall, as expected, these data clearly show knockdown of SSU proteins affects the mitochondrial protein translation and reduces the bc1 activity.

Loss of PfmtRPS12 causes a hypersensitivity to mtETC-targeting drugs

The mitochondrion of Plasmodium has been successfully exploited as a major antimalarial drug target [21]. As illustrated in Fig. 6A, the bc1 complex is the target of the clinical drug atovaquone, the preclinical candidate ELQ-300, and other inhibitors in the development pipeline [21]. The de novo pyrimidine biosynthetic enzyme, dihydroorotate dehydrogenase (DHOD), is the target of DSM-265, a candidate currently under development.
undergoing a Phase IIa clinical trial (45). Complex V (F1F0-ATP synthase) is believed to be the target of proguanil (46), the second compound in the registered drug Malarone (a combination of atovaquone and proguanil). All of these drugs target mtETC-related proteins (Fig. 6A). We investigated whether disruption of the Plasmodium mitoribosome would have a synergistic

**Figure 6.** Knockdown PfmrRPS12 renders the parasite to become hypersensitive to inhibitors targeting mitochondrial functions. A, the Plasmodium mtETC and F1F0-ATP synthase complex; G3PDH, glycerol-3-phosphate dehydrogenase; MQO, malate-quinone oxidoreductase; NDH2, ubiquinone oxidoreductase; DHOD, the target of DSM-265; SDH, succinate dehydrogenase; cyt c, soluble cytochrome c; Q, ubiquinone; QH2, ubiquinol. bc1 complex Qo site, the target of atovaquone and CK-2–68. bc1 complex Qi site, the target of ELQ-300, HDQ; complex V, F1F0-ATP synthase, the target of proguanil. B, hypersensitivity to DSM-265, atovaquone, CK-2–68, ELQ-300, HDQ, and proguanil in PfmrRPS12 knockdown parasites. Data shown are the mean ± S.D. of duplicates and are representative of n = 3 independent experiments. Chloroquine and artemisinin served as controls.
Small subunit proteins in the *P. falciparum* mitoribosome

effect on the action of antimalarial drugs that inhibit enzymes of the mtETC. In our previous report (36), the PfmtRPL13 knockdown line was generated using the pre-guide RNA (gRNA) construct carrying Cas9 and the yeast DHOD (yDHOD). Previous studies revealed that heterologous expression of yDHOD in *P. falciparum* rendered the parasite insensitive to atovaquone and other mtETC drugs (46); thus, the PfmtRPL13 line was not suitable for testing drugs related to mitochondrial functions. Here, we generated the three SSU knockdown lines using a pre-gRNA construct lack of yDHOD (“Experimental procedures”), which are suitable for drug testing.

We performed standard 3-day SYBR Green I drug inhibition assays beginning with ring-stage parasites in the presence or absence of aTc. Because removal of aTc affected the SSU lines distinctly (Fig. 4), we started drug assays after prior removal of aTc for 1.5 IDCs with the D10-PfmtRPS17–3HA line, 2.5 IDCs with the D10-PfmtRPS12–3HA line, and 4.5 IDCs with the D10-PfmtRPS18–3HA line. For instance, in the case of the PfmtRPS12 line, the drug assay covered days of 5–8 post-aTc removal, which is when the parasites begin to exhibit a measurable growth defect. As shown in Fig. 6B, upon removal of aTc, PfmtRPS12 parasites displayed hypersensitivity to DSM-265, atovaquone, CK-2–68 (another bc₁ inhibitor) (47), ELQ-300, HDQ (another bc₁ inhibitor) (48), and proguanil. As controls, these parasites did not exhibit hypersensitivity to drugs that do not target the mtETC or related mitochondrial processes, e.g. chloroquine and artemisinin. Hence, the hypersensitivity to DSM-265, proguanil, and other mtETC-targeting drugs observed in D10-PfmtRPS12–3HA parasites was specific to aTc removal, not likely due to a secondary nonspecific effect. In addition, D10 WT parasites were also tested with the same panel of drugs in the presence and absence of aTc, and they did not show any differences in drug sensitivity (Fig. 6). Together, these results provide strong evidence that genetic ablation of the *Plasmodium* mitoribosome sensitizes the parasite to antimalarial drugs targeting the mtETC and Complex V.

Interestingly, however, this synthetic lethality only occurred in the PfmtRPS12 line, in which a genetic knockdown caused a significant fitness cost but did not severely affect parasite growth. In PfmtRPS18 parasites, they responded to all the tested drugs in a similar manner with or without aTc (Fig. S5). This was likely because knockdown of PfmtRPS18 did not result in any defects in parasite growth (Fig. 4 and Fig. S4C). On the other hand, knockdown of PfmtRPS17 had a dramatic effect by itself. When combined with antimalarial drugs, PfmtRPS17 knockdown parasites exhibited hypersensitivity to all the drugs tested in a nonspecific manner, including DSM-265, atovaquone, CK-2–68, ELQ-300, HDQ, proguanil, chloroquine, and artemisinin (Fig. S5) (see “Discussion”).

**Metabolic profiling upon knockdown of PfmtRPS17**

In the data described above, we observed that genetic knockdown of SSU proteins in the *Plasmodium* mitoribosome resulted in parasite growth arrest (Fig. 4, PfmtRPS12/ PfmtRPS17), reduction of bc₁ activity (Fig. 5, all lines), and synthetic lethality with antimalarials targeting the mtETC (Fig. 6, PfmtRPS12). Because in asexual blood stages the parasite mitochondrion does not synthesize a significant amount of ATP via oxidative phosphorylation, but primarily acts as a metabolic hub, we hypothesized that knocking down the mitoribosome could perturb the metabolic stability of the parasite mitochondrion. To address this, we chose to work with the D10-PfmtRPS17–3HA line, because severe growth arrest of this line was triggered in a short period of time upon removal of aTc. As shown above (Fig. 4 and Fig. S4), in the absence of aTc, although PfmtRPS17 parasites showed no noticeable growth arrest in the 1st IDC (48 h), they displayed a reduced parasitemia and abnormal morphologies in the 2nd IDC (96 h). Therefore, we set up the knockdown experiment and extracted metabolites for metabolomic analysis every 12 h between 24 and 96 h post-aTc removal. Hence, samples at 7 time points were collected from both cultures grown with and without aTc (“Experimental procedures”). This time course covered the time period before and after growth arrest of PfmtRPS17 parasites took place. However, it did not include samples of IDCs 3 and 4 when parasites were too severely ill and a metabolic perturbation could be a secondary effect of parasite death. As a positive control, PfmtRPS17 parasites grown in the presence of aTc were treated with 10 nM atovaquone for 4 h, and their metabolites were extracted and analyzed (“Experimental procedures”).

As shown in Fig. S6, we detected a total of 104 metabolites in the time course samples, including metabolic intermediates of nucleotide metabolism, TCA cycle, glycolysis, amino acid metabolism, pyrimidine biosynthesis, and others. In the first three time points (24, 36, and 48 h), knocking down PfmtRPS17 led to fluctuations in the levels of many metabolites, but none decreased or increased in abundance by more than 2-fold in the absence of aTc. These data again indicate that PfmtRPS17 parasites were largely healthy upon removal of aTc for 1 IDC. However, beyond the time point of 60 h, the levels of the pyrimidine *de novo* synthesis pathway intermediates, *N*-carbamoyl-1-aspargate and dihydroorotate, increased significantly in the knockdown parasites (Fig. 7). As a positive control, atovaquone treatment in PfmtRPS17 parasites grown under aTc also resulted in accumulations of these two intermediates. As shown previously (49), blockage of pyrimidine biosynthesis is a classical metabolic signature of antimalarial drugs targeting the parasite mtETC, because a direct chemical inhibition of mtETC subsequently blocks the activity of parasite DHOD (46). On the other hand, from the time points of 84 h and beyond, 10 metabolites in the pyrimidine nucleotide pool and TCA cycle decreased in abundances by more than 2-fold in the absence of aTc (metabolites 1–10, Fig. S6). In atovaquone-treated samples, three of these metabolites (dTDP, CDP, and citrate/isocitrate) also displayed >2-fold decrease in their relative abundances. Overall, our data show knockdown of the *Plasmodium* mitoribosome largely recapitulates the effect of atovaquone on inhibiting pyrimidine biosynthesis.

**Discussion**

With the exception of one anaerobic protist that has lost its mitochondrial-related organelle (50), all eukaryotic organisms contain mitochondria or mitochondrally-derived organelles (e.g. mitosomes). In model systems like yeast and human cells, the mitochondrion is often considered the “power house” of the
cell; however, ATP synthesis via oxidative phosphorylation is not always a major contribution of the mitochondrion in some deeply divergent parasitic protozoans (51). For example, in the blood stage infection of *Plasmodium* spp., the parasite mitochondrion mainly serves as a metabolic hub to provide essential metabolites, *e.g.* pyrimidine precursors, ubiquinone, iron-sulfur clusters and more. To fulfill these metabolic roles, a functional mtETC is needed to pump protons across the MIM to build up a proton electrochemical gradient, with the mitochondrial membrane potential, $\Delta \Psi_m$, as its major component. The energy saved in $\Delta \Psi_m$ is then utilized by the mitochondrion to import proteins and metabolic precursors from the cytosol. Although many mtETC subunit proteins are nuclearly encoded in apicomplexan parasites, as in other eukaryotes, three highly hydrophobic transmembrane proteins (*cyt b*, *cox1*, and *cox3*) have been evolutionarily retained on the mtDNA and are translated inside the mitochondrion. Despite the significance of mtETC in apicomplexan parasites, few studies have been done to understand mechanisms of mitochondrial protein translation. It was only recently demonstrated that the mitoribosome is absolutely essential in these parasites (36, 38). In this work, we performed genetic, biochemical, and functional analyses to further study the mitoribosome in *P. falciparum*.

**What can we learn about the Plasmodium mitoribosome from genetic studies?**

Similar to what we previously reported using an LSU-tagged line (PfmtRPL13) (36), knockdown of SSU proteins in the *Plasmodium* mitoribosome resulted in a series of lethal events, including reduction of $bc_1$ activity (Fig. 5), collapse of parasite morphology (Fig. S4), and loss of parasitemia (Fig. 4). However, our data also yield important insights into the distinct roles of SSU proteins in the *Plasmodium* mitoribosome. As shown in Fig. 4, knockdown of each of the three SSU proteins affected the mitoribosome to varying degrees from negligible (*PfmtRPS18*) to mild (*PfmtRPS12*) and severe (*PfmtRPS17*). The nonessential nature of *PfmtRPS18* was also reported in a recent comprehensive piggyBac-insertion mutagenesis screen (44), although the homolog of the rodent malaria parasite *Plasmodium berghei* appears to be essential (52). *S12* is essential in both *P. berghei* (52) and *P. falciparum* (44) (not assessed in *P. berghei* (52)). We reason that the position of a particular SSU protein inside the mitoribosomal complex is critical for its function. Unfortunately, to date, no structure of a mitoribosome or ribosome comprised of many fragmented rRNAs is available. Hence, it is difficult to explain why all SSU proteins of the *Plasmodium* mitoribosome are not critical. As shown in Fig. 1, we mapped...
the available rRNA fragments and 14 SSU proteins of the *Plasmodium* mitoribosome to the bacterial 30S ribosome. In the bacterial ribosome, S17 is one of the earliest proteins to bind the 5’ end of 16S rRNA and directly interacts with helices H7 and H11 (42). Although PfmtRPS17 has relatively low sequence similarity with the bacterial homolog (27% identity), a predicted structure of PfmtRPS17 by I-Tasser (53) is superimposable on the crystal structure of bacterial S17 (data not shown). Moreover, RNA12 in the *Plasmodium* mitoribosome is homologous to the region of 16S rRNA where helices H7 and H11 are located (13, 17). These considerations combined with our data suggest that the absolute necessity of PfmtRPS17 likely involves direct binding of the protein to rRNA (likely, RNA12). However, whether PfmtRPS12 or PfmtRPS18 could directly bind to rRNA remains unknown (or unpredictable) at present.

**How is a mitoribosome attached to the mitochondrial inner membrane?**

For the first time, we have demonstrated a close association of the mitoribosome to the MIM in an apicomplexan parasite (Fig. 3). Compared with other ribosomes, a unique feature of the mitoribosome is that all or most of its protein translation products are highly hydrophobic mtETC subunits. Studies of mammalian mitoribosomes with cryo-electron tomography have clearly shown the physical attachment of the mitoribosome to the MIM (40). In yeast and mammals, an increasing list of factors has been found that participate in mediating the interaction of the mitoribosome and the MIM in a structure called the mitoribosomal interactome. For example, the mitoribosomal protein MrpL45 (40) (UniProtKB-Q9BRJ2) and the MIM receptors (54), Mba1 (YBR185C) and Mrx15 (YNR040W), are critical subunits of the mitoribosomal interactome. However, a homology search using sequences of these proteins in PlasmoDB failed to identify any homologous proteins in *Plasmodium*, suggesting that the molecular partners of the mitoribosomal interactome in malaria parasites are highly divergent, and, if identified, they may be exploited to develop selective antimalarial inhibitors.

**Is the Plasmodium mitoribosome a good antimalarial drug target?**

Previous studies have validated two antimalarial drug targets, *bc*, and DHOD, in the *Plasmodium* mitochondrion. Inhibition of *bc* blocks the recycling of ubiquinone and in turn shuts down ubiquinone-dependent enzymes in the mtETC, including DHOD, which is essential in the pyrimidine biosynthesis pathway (46). Disruption of the *Plasmodium* mitoribosome simultaneously diminishes core components of the mtETC and DHOD. As shown in Fig. 7 and Fig. S6, knockdown of the mitoribosomal SSU (in D10-PfmtRPS17–3HA line) phenocopied the metabolic effect of atovaquone on the parasite. In particular, 60–96 h post-aTc removal, we observed an accumulation of pyrimidine biosynthesis intermediates, *N*-carbamoyl-L-aspartate and dihydroorotate, and a concurrent decrease in pyrimidine nucleotides (thymine/cytosine/uracil mono/diphosphate). Importantly, these metabolic changes emerged at a point when the parasites started to display noticeable growth defects, suggesting that a metabolic blockade of the pyrimidine biosynthetic pathway was primarily responsible for parasite death. Although we did not test metabolic profiles in the parasites when aTc was removed for longer than 2 IDCs, we expect continued knockdown of PfmtRPS17 would further reduce the pyrimidine pool and cause other abnormalities leading to parasite death.

Besides DHOD and pyrimidine metabolism, ablation of mitochondrial protein translation would also abolish other essential metabolic pathways of the mitochondrion. One of those is iron-sulfur (Fe-S) cluster biosynthesis. Fe-S cluster containing proteins are widely distributed in the nucleus and cytosol and are involved in numerous biochemical pathways, such as electron transfer, catalysis, DNA repair, and ribosome biogenesis (55, 56). As in other eukaryotes, the mitochondrial Fe-S cluster biogenesis pathway in *Plasmodium* provides these redox centers to proteins in extra-mitochondrial compartments, as well as the mitochondrion. Indeed, the most conserved function of mitochondria or mitochondrially derived organelles is synthesis of iron-sulfur clusters. For instance *Cryptosporidium*, another apicomplexan parasite, maintains several mitosomes per cell to accommodate Fe-S biosynthesis even though this genus lacks mtDNA (57). Malaria parasites contain dozens of proteins needed to perform Fe-S cluster biogenesis in the mitochondrion (4). However, these proteins are generally very similar to the counterparts in yeast and humans; thus, the likelihood of selectively inhibiting the parasite’s mitochondrial Fe-S cluster biogenesis is potentially low. As shown previously, disruption of the *Plasmodium* mitoribosome collapses ΔΨm (36). Although not directly tested, we speculate that genetic ablation of the *Plasmodium* mitoribosome subsequently blocks the mitochondrion’s ability to synthesize Fe-S clusters, due to the reduced ΔΨm, which hinders import of the enzymes involved in Fe-S cluster biogenesis, and contributes to parasite demise.

Furthermore, we found that genetic knockdown of the *Plasmodium* mitoribosome had a synergistic effect with antimalarial drugs targeting the mitochondrion in the D10-PfmtRPS12–3HA line, in which a genetic ablation caused a significant but not severe growth failure (Fig. 6). As shown in Fig. S5, knockdown of PfmtRPS18 did not affect parasite fitness, so the parasites responded to drugs in a similar way regardless of the growth condition (with or without aTc). However, in the D10-PfmtRPS17–3HA line, knockdown itself was severely detrimental, and increasing concentrations of drug had a minor role. Thus, the parasite became hypersensitive to antimalarials targeting both mitochondrial and extra-mitochondrial pathways (Fig. S5). Together, our studies suggest that the *P. falciparum* mitoribosome is a good antimalarial drug target. We predict chemical disruption of the *Plasmodium* mitoribosome, if suitable inhibitor compounds were to be developed, would simultaneously impact multiple essential pathways in the parasite mitochondrion. Hence, future inhibitors targeting the *Plasmodium* mitoribosome should be good partner drugs in combination with antimalarials targeting either the mitochondrion or other cellular pathways.
**Experimental procedures**

**Plasmid construction**

The pAll-In-One (pAIO) vector was kindly provided by Dr. Joshua Beck, Iowa State University (58). This plasmid bears Cas9 from *Streptococcus pyogenes* and a gRNA expression cassette. The Cas9 CDS is flanked by an yDHOD (yeast DHOD) minus of Cas9, yielding another construct named NF-Cas9-yDHOD (−). In M-Cas9-yDHOD (−), we removed the FLAG tag at the C terminus of Cas9, yielding another construct named NF-Cas9-yDHOD (−). All gRNAs used in this study were selected based on analysis by the Eukaryotic Pathogen CRISPR guide RNA Design Tool (RRID: SCR_018297). gRNAs were individually cloned into NF-Cas9-yDHOD (−) using DNA-assembly reactions (NEBuilder HiFi DNA Assembly Master Mix, New England Biolabs, Inc.). The TetR-DOZI-aptamer conditional knockdown system was kindly provided by Dr. Jacquin Nile's group at MIT (37). From the original pMG75-ATP4 vector bearing the TetR-DOZI and aptamer elements, we removed the attP sequence and replaced the single epitope sequences with a 3HA tag in our previous report (36). In the modified vector, we cloned two homologous regions (5'HR and 3'HR) from each SSU gene individually. Details of all cloning steps are available under the Supporting Data. Primers used for cloning are listed in Table S1.

**Parasite lines, parasite culture, and transfection**

D10 WT *P. falciparum* was used in this study. Asexual *P. falciparum* parasites were cultured with RPMI 1640 medium supplemented with 0.5% Albumax I (Gibco by ThermoFisher Scientific), sodium bicarbonate (2.1 g/liter, Corning by Fisher Scientific, HEPES (15 mM, MilliporeSigma), hypoxanthine (10 mg/liter, Fisher Scientific), and gentamycin (50 mg/liter, VWR) and maintained as previously described (36). Prior to transfections, template vectors were digested by a specific restriction enzyme overnight to linearize the plasmid (pMG75noP-PfmRPS12–8apt-3HA) was digested with EcoRV, pMG75noP-PfmRPS17–8apt-3HA and pMG75noP-PfmRPS18–8apt-3HA by SacII). Electroporations were performed in cultures of 5–6% rings added with linearized template plasmids (40 μg/electroporation) together with circular gRNA plasmids (50 μg of gRNA/electroporation). Post-electroporation, parasites were cultured with anhydrotetracycline medium at 250 nm (aTc+, MilliporeSigma) for 2 days before blasticidin/aTc+ medium was used (blasticidin at 2.5 μg/ml, InvivoGen). To keep parasite cultures healthy, unless specified, we maintained the cultures in *vitro* below a parasitemia of 5%.

**Western blotting**

Parasitized cultures were treated with saponin (0.05%) in PBS supplemented with a 1X protease inhibitor mixture (P8215, MilliporeSigma). The parasitized pellet was resuspended in ~10 volumes of 2% SDS, 62 mM Tris–HCl (pH 6.8) and mixed by repeated pipetting. The sample was further mixed on a tube rotator for 4–6 h at room temperature or overnight at 4 °C. The lysate was spun down at top speed for 5 min and the supernatant was used for SDS-PAGE. The blot was blocked and incubated with a mouse monoclonal anti-HA primary antibody (sc-7392, Santa Cruz Biotechnology) at 1:7,500 and a horseradish peroxidase-conjugated secondary goat anti-mouse antibody (A16078, ThermoFisher Scientific) at 1:10,000. The blot was later probed with a rabbit anti-PfExp2 primary antibody (a gift from Dr. James Burns at Drexel University) at 1:10,000 followed by a horseradish peroxidase-conjugated secondary goat anti-rabbit antibody (31460, ThermoFisher Scientific) at 1:20,000. Other steps followed the standard protocol.

**Immunofluorescence assay**

Parasite cultures of a 50-μl packed volume were pre-labeled with 60 nm MitoTracker Red CMXRos (Life Technologies by ThermoFisher Scientific) for 30 min and washed three times with PBS to remove extra MitoTracker. The cells were fixed with 4% paraformaldehyde, 0.0075% glutaraldehyde for 1 h at 37 °C on a rotator. They were washed, permeabilized with 0.5% Triton X-100, PBS for 10 min, treated with 0.1 mg/ml of NaBH4 for 5 min, and blocked with 5% BSA overnight. The parasites were incubated with the HA probe (sc-7392, Santa Cruz Biotechnology) at 1:250 overnight at 4 °C, washed three times with PBS, and added with the secondary antibody (Alexa Fluor 488-conjugated anti-mouse antibody, Life Technologies by ThermoFisher Scientific) at 1:250 overnight at 4 °C. The parasites were washed 3 times with PBS, resuspended in anti-fade buffer (S8282, ThermoFisher Scientific), and visualized under a Leica SP8 confocal microscope. Images were processed using Leica Application Suite X software.

**Immun-EM**

The D10-PfmRPS18–3HA culture was synchronized with alanine (0.5 mM in 10 mM HEPES, pH 7.6) and enriched by a MACS Cell Separation Column (MiltenyiBiotec) at trophozoite stages to reach a high parasitemia (~95%). The enriched parasites in a volume of 25–50 μl were fixed with 1 ml of 2% paraformaldehyde, 2.5% glutaraldehyde, 100 mM sodium cacodylate at room temperature on a rotator for 1 h. Samples were washed in sodium cacodylate buffer, embedded in 10% gelatin, and infiltrated overnight with 2.3 mM sucrose, 20% polyvinyl pyrrolidone in PIPES/MgCl2 at 4 °C. Samples were trimmed, frozen in liquid nitrogen, and sectioned with a Leica Ultracut UCT7 cryo-ultramicrotome (Leica Microsystems Inc.). Ultrathin sections of 50 nm were blocked with 5% fetal bovine serum, 5% normal goat serum for 30 min and subsequently incubated with mouse anti-HA (sc-7392, Santa Cruz Biotechnology) for 1 h at room temperature. Following washes in blocking buffer, sections were incubated with goat anti-mouse IgG (H + L) 18 nm colloidal gold-conjugated secondary antibody (Jackson ImmunoResearch Laboratories) for 1 h. Sections were stained with
**Small subunit proteins in the *P. falciparum* mitoribosome**

0.3% uranyl acetate, 2% methyl cellulose and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc.) equipped with an AMT 8 megapixel digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques). All labeling experiments were conducted in parallel with controls omitting the primary antibody. These controls were consistently negative at the concentration of colloidal gold-conjugated secondary antibodies used in these studies. Immuno-EM was performed at the Molecular Microbiology Imaging Facility at Washington University, St. Louis, MO.

**Parasites growth curves and knockdown experiment**

Parasite cultures were tightly synchronized with several rounds of alanine treatment (0.5 M alanine, 10 mM HEPES, pH 7.6) and trophozoite/schizont stages were isolated using a Percoll gradient (89428–524, GE Healthcare Life Sciences). The highly enriched parasites were washed 3 times with regular RPMI (aTc⁻) and inoculated into two new T25 flask: Each containing ~10 μl of parasitized pellet, 1 ml of fresh blood and 10 ml of medium with or without aTc (aTc⁺, aTc⁻). In the next few IDCs, cultures were split 1:5 every cycle. At each split, 80% of the culture from aTc⁺ and aTc⁻ conditions was used to collect protein samples for Western blot analysis. Thin blood smears were made from both cultures to monitor parasitemia, which was determined from counting 1000 red blood cells (RBC) per smear under a Leica light microscope.

**Mitochondrion preparation (Mito-prep) and bc₁ complex enzymatic activity measurement**

For each parasite line (D10-PfmRPS12–3HA, D10-PfmRPS17–3HA, or D10-PfmRPS18–3HA), two mito-preps were done to isolate a cellular fraction enriched in parasite mitochondria from parasites grown with or without aTc. With parasites grown in the presence of aTc, each line was tightly synchronized with alanine and expanded to a large volume (8–10 T175 flasks). The saponintreated parasite pellet was disrupted using a nitrogen cavitation at 1000 p.s.i. and passed through a MACS CS column (Miltenyi Biotec) to remove the majority of hemozoin. The eluted material from the magnetic column was spun down at 23,000 × g. This material contains enriched mitochondria or mitochondrial membranes and is suitable for *in vitro* bc₁ enzymatic assay, as shown in our previous studies (36, 61). For parasites grown in the absence of aTc, cultures were first grown in aTc⁺ medium to a moderate volume (2–3 T175 flasks) and parasites were isolated by a Percoll gradient and inoculated into new T175 flasks supplemented with fresh blood and regular medium (no aTc). The aTc⁻ cultures were maintained for a desired time period and mito-prep was done after removal of aTc for 2 IDCs (D10-PfmRPS17–3HA), 4 IDCs (D10-PfmRPS12–3HA), or 5 IDCs (D10-PfmRPS18–3HA) using the same procedure as described above. For *in vitro* bc₁ enzymatic assay, the cytochrome c reductase activity of the bc₁ complex was determined using a CLARiTY integrating spectrophotometer (OLIS, Bogart, GA). Briefly, the progress of a 300 μl of cyt c reductase reaction, which consisted of mito-prep samples (containing bc₁ complex), reduced decylubiquinol (electron donor), oxidized horse heart cytochrome c (electron acceptor), and KCN (inhibiting Complex IV activity) in buffer at pH 7.4, was recorded at 550 nm using the spectrophotometer. Other procedures followed our published studies (36, 48).

**Drug sensitivity assay (the malaria SYBR Green I-based fluorescence assay, MSF)**

Compounds used in this study included DSM-265 (HY-100184, MedCamExpress), atovaquone (A7986, MilliporeSigma), ELQ-300 (synthesized as previously described (24)), prophagin (G7048, MilliporeSigma), artemisinin (a gift from Dr. Jianping Song at Guangzhou University of Chinese Medicine, China), and chloroquine (AC455240250, Fisher Scientific). MSF assays were performed based on published protocols (62, 63). Briefly, parasites cultured in aTc⁺ or aTc⁻ medium were exposed to drugs diluted in serial dilutions for 72 h (starting from ring stage parasites). Then the culture was lysed with buffer containing SYBR Green I and examined for relative fluorescence units with a Tecan plate reader (Infinite F PLEX). Details of setting up the assay and analyzing the data are available under the Supporting Data.

**Metabolic profiling of PfmRPS17 line**

The parasite line D10-PfmRPS17–3HA was synchronized and expanded to a moderate volume (2–4 T175 flasks) and late stage parasites (trophozoite/schizont) were isolated using a Percoll gradient. The purified parasites were evenly inoculated into two new flasks, added with fresh blood and maintained with or without aTc (time 0). Twenty-four h post-time 0, metabolites from aTc⁺ and aTc⁻ cultures were collected every 12 h up to 96 h (in total of 7 time points). The extracted metabolites were analyzed following a published protocol (49). Other details are provided under the Supporting Data.

**Data availability statement**

All data of this manuscript have been contained within this manuscript.


**Acknowledgments**—We are grateful for the active support from members of the Center for Molecular Parasitology, Department of Microbiology and Immunology at Drexel University College of Medicine. We thank Dr. Josh Beck (Iowa State University), Dr. Jacquin Niles (MIT), Dr. James Burns (Drexel University), and Dr. Jianping Song (Guangzhou University of Chinese Medicine, China) for sharing plasmid vectors and reagents. We thank Dr. Wendy Beatty at the Molecular Microbiology Imaging Facility at Washington University in St. Louis for conducting immuno-EM studies.

**References**

Small subunit proteins in the P. falciparum mitoribosome


Genetic ablation of the mitoribosome in the malaria parasite *Plasmodium falciparum* sensitizes it to antimalarials that target mitochondrial functions

Li Qin Ling, Maruthi Mulaka, Justin Munro, Swati Dass, Michael W. Mather, Michael K. Riscoe, Manuel Linás, Jing Zhou and Hangjun Ke

doi: 10.1074/jbc.RA120.012646 originally published online April 9, 2020

Access the most updated version of this article at doi: 10.1074/jbc.RA120.012646

Alerts:  
- When this article is cited  
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 60 references, 18 of which can be accessed free at http://www.jbc.org/content/295/21/7235.full.html#ref-list-1